All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Oncology Experts Preview Top Abstracts to be Shared at 2025 ASCO GI

January 22nd 2025

Tanios S. Bekaii-Saab, MD, and Yelena Y. Janjigian, MD, preview top presentations from this year’s Gastrointestinal Cancers Symposium.

Ibrutinib/Venetoclax Combo Demonstrates Sustained TEAE-Free PFS in First-Line CLL

January 22nd 2025

Carsten Utoft Niemann, MD, PhD, discusses improvements in toxicity-free survival with ibrutinib and venetoclax in CLL.

SHR-A1811 Maintains Efficacy, Safety in Pretreated HER2-Expressing/-Mutated Breast Cancer, Other Solid Tumors

January 22nd 2025

An additional 1-year of follow-up confirmed the safety and activity of SHR-A1811 in HER2-expressing or -mutant solid tumors, including breast cancer.

IO-202 Plus Azacitidine Could Bring Long-Awaited Change in HMA-Naive CMML

January 22nd 2025

Gabriel Mannis, MD, discusses the observed clinical activity and manageable safety profile of IO-202 combined with azacitidine in CMML.

Dana-Farber Brigham Cancer Center Recognized for Exceptional Outcomes in Adult Donor Stem Cell Transplants for Fifth Consecutive Year

January 22nd 2025

Stem cell transplant programs at the Dana-Farber Brigham Cancer Center received outstanding reviews from the CIBMTR.

Isatuximab Plus VRd Wins EU Approval for Newly Diagnosed, Transplant-Ineligible Multiple Myeloma

January 22nd 2025

The EMA’s CHMP has approved isatuximab in combination with VRd for transplant-ineligible patients with newly diagnosed multiple myeloma.

Felix Y. Feng, MD, Leading Radiation Oncologist and Genitourinary Cancer Researcher, Dies at 48

January 22nd 2025

Felix Y. Feng, MD, a radiation oncologist and researcher at UCSF, died of cancer on December 10, 2024, at 48 years old.

Second Cycle of Medicare Drug Price Negotiations Includes 4 Oncologic Agents

January 22nd 2025

The CMS has selected 15 drugs covered under Medicare Part D for the second cycle of the Drug Price Negotiation Program, including enzalutamide, pomalidomide, palbociclib, and acalabrutinib.

2024 FDA Approvals Highlight New Treatment Considerations in HR+ Breast Cancer

January 22nd 2025

Eric Winer, MD, discusses the significance of 2 FDA approvals for HR-positive, HER2-negative breast cancer and emerging novel breast cancer treatments.

UGN-102 Shows Favorable Risk-Benefit Profile, Sustained CR Rates in Low-Grade, Intermediate-Risk NMIBC

January 22nd 2025

Durable responses with UGN-102 signal its viability as a nonsurgical alternative to TURBT in low-grade, intermediate-risk NMIBC.

Everolimus Plus Lanreotide Extends PFS in Advanced GEP-NETs

January 21st 2025

Everolimus plus lanreotide demonstrated an improved PFS compared with everolimus monotherapy in gastroenteropancreatic neuroendocrine tumors.

Quantitative IHC Assays May Bridge Gaps in Breast Cancer IHC Test Concordance

January 21st 2025

David Rimm, MD, PhD, discusses pathology limitations that have been exacerbated by the current lineup of breast cancer IHC tests.

Precision Medicine Heats Up Ahead of SOGO Annual Meeting in GI Cancer

January 21st 2025

E. Gabriela Chiorean, MD, discusses exciting targeted therapies in the GI space and topics to be discussed at the School of Gastrointestinal Oncology meeting.

Fox Chase Cancer Center’s Roland Dunbrack Appointed Co-Leader of the Cancer Signaling and Microenvironment Program

January 21st 2025

Roland Dunbrack, PhD, of the Cancer Signaling and Microenvironment Research Program at Fox Chase Cancer Center, was appointed co-leader of the program.

FDA Grants Priority Review to RP1 Plus Nivolumab for Advanced Melanoma After Anti–PD-1 Therapy

January 21st 2025

The FDA granted priority review to the BLA for RP1 plus nivolumab in advanced melanoma following progression on an anti–PD-1 agent.

First-Line Amivantamab Plus Lazertinib Wins EU Approval for EGFR+ Advanced NSCLC

January 21st 2025

The European Commission approved first-line amivantamab plus lazertinib for EGFR-mutated advanced non–small cell lung cancer.

ACS Annual Report Shows Cancer Incidence Rates Are Rising in Select Populations

January 21st 2025

The 2025 American Cancer Society Annual Report Showed incidence rates are increasing for many cancer types and disparities remain regarding cancer mortality.

TKIs Look to Solidify a Role Alongside T-DXd in the Second-Line HER2-Mutant NSCLC Setting

January 21st 2025

The second-line setting for HER2-mutated NSCLC is shifting with TKIs looking to demonstrate efficacy and T-DXd under examination in the frontline now.

Rapid, At-Home PSA Screening Test Gains Approval in UAE for Early Detection of Prostate Cancer

January 21st 2025

The Fortel PSA Screening Test has been approved by the United Arab Emirates MOHAP for the rapid detection of early signs of prostate cancer.

AVA6000 Elicits Clinically Meaningful Tumor Shrinkage in Salivary Gland Cancer

January 20th 2025

Preliminary data show that AVA6000 led to robust and clinically meaningful tumor shrinkage in patients with salivary gland cancer.